Skip to content
orbyd

Dossier · STRO · Dormant

STRO

MEDIUM a5Earnings inflection

Last analysed · · source: watchlist_research

Current thesis

Sutro burned its old story (deprioritized lead luvelta) and re-minted the equity around STRO-004, a "best-in-class" Tissue Factor ADC. Barclays init OW $56 (2026-05-28) + analyst cluster into a mid-2026 Phase 1 readout. Post 1:10 reverse split the stock 5x'd off lows to ~$29 — the whole trade is the binary STRO-004 data.

Invalidation trigger

Weekly close below ~$22 (20-week EMA) on volume, OR STRO-004 mid-2026 Phase 1 initial data shows DLTs / no objective responses. Secondary tell: a fresh dilutive raise pre-catalyst or the luvelta out-licensing process collapsing.

Thesis status

Open commitment scored if the trigger above fires How this is scored →

Current Thesis

Clinical-stage ADC shop that burned its old story and minted a new one. Sutro deprioritized its former lead luvelta (luveltamab tazevibulin, FRα ADC) in early 2026 — out-licensing it despite a 32% ORR in platinum-resistant ovarian (SGO 2026) — and repositioned the entire equity around STRO-004, a "potential best-in-class" Tissue Factor (TF) ADC now in Phase 1 dose escalation. Wall Street is buying the reset: Barclays initiated Overweight, $56 PT on 2026-05-28, a sell-side desk reaffirmed Buy on 2026-06-01 citing STRO-004 optionality, and Simply Wall St flagged analysts raising revenue forecasts +46%. Post 1-for-10 reverse split (Dec 2025) the stock has run from [entry redacted] to a $43.85 high and sits ~$29 (2026-06-04, +7.65% intraday). This is an archetype-5 binary: the whole trade is the STRO-004 initial Phase 1 safety/PK/early-activity readout guided for mid-2026.

Bull Case

  • Narrative reset + analyst cluster confirming: Barclays OW $56 (2026-05-28) → reaffirmed Buy 2026-06-01 → 12-analyst Strong Buy consensus, avg PT $48.17 (~65% above ~$29). Cluster of fresh sell-side initiations 1-2 weeks before a catalyst is exactly the acceleration signal we buy.
  • Hot theme, real M&A bid: ADC / precision-oncology remains a deal-magnet sector (Pfizer-Seagen, AbbVie-ImmunoGen, Merck-Daiichi). A clean STRO-004 TF-ADC readout puts STRO on the partnership/M&A radar at a $485M cap.
  • Preclinical de-risking: AACR 2026 (April) data showed "robust, consistent antitumor activity" for STRO-004 plus a dual-payload STRO-227 program — supports the best-in-class framing into the human readout.
  • Funded through the catalyst: $202.6M cash (3/31/2026) after a Feb 2026 $110M raise → runway into at least Q2 2028. No financing overhang forcing a desperate raise before STRO-004 data.
  • Loss narrowing: Q1 2026 net loss $38.5M vs $76.0M YoY on post-restructuring opex cuts — cleaner burn profile.

Bear Case

  • They walked away from their own lead. Deprioritizing luvelta after years of investment is a track-record red flag (Seeking Alpha: "ADC developer with poor track record"). The new "best-in-class" claim is preclinical until proven in humans.
  • Binary, early-stage data. STRO-004 mid-2026 readout is Phase 1 dose-escalation: small N, early activity signal. A DLT/safety flag or zero objective responses gaps this 30-50% lower — there is no franchise revenue to cushion it.
  • 5x off the lows = extended. Run from [entry redacted] to $43.85, now ~$29 (off ~33% from highs). Buying here is buying into a name that already went semi-public.
  • Serial diluter. Feb 2026 offering (7.87M shares, ~$110M) and a 1-for-10 reverse split in Dec 2025 — the reverse split itself signals prior price distress. Shares out 16.57M and climbing.
  • Astellas collab revenue fading: Q1 2026 revenue $14.5M down from $17.4M YoY — the non-dilutive partnership income is shrinking.

Setup & Price Structure

  • Last ~$29.26 (2026-06-04, +7.65% on the day; prior close $27.18; day range $27.00–$30.94).
  • 52-wk range $6.74 → $43.85 (post 1:10 reverse split). Currently ~33% below the high, bouncing off a pullback — not at fresh highs, not broken.
  • Market cap ~$485M; ~16.57M shares; beta 1.55 (high-vol biotech tape).
  • Structure: pulled back from [entry redacted] basing/rebounding in the high-$20s. A reclaim and hold above ~$31 (recent supply) confirms the leg back up; failure to hold the low-$20s breaks it.

Catalyst Calendar (next 30 days)

  • ~mid-2026 (est., likely June–Aug 2026) — STRO-004 Phase 1 initial data (safety, PK, early activity). THE binary. No confirmed date; treat any long position in the coming weeks as a bet into an unscheduled readout.
  • 2026 (H2, est.) — IND filings for STRO-006 and dual-payload STRO-227. Pipeline-breadth catalysts, lower magnitude.
  • 2026-06-01 — sell-side Buy reaffirmation (already printed). Watch for further initiations clustering into the readout.
  • No earnings inside 30d (Q1 reported ~May 2026; next print ~Aug 2026).

What Would Change Our Mind

  • Bull-confirming: STRO-004 initial Phase 1 data shows objective responses with clean safety → repricing toward the $48–$56 PT band; theme stays ACCELERATING; add on a clean breakout-retest above ~[entry redacted]
  • Bear-confirming / exit: STRO-004 readout shows DLTs or no objective responses; weekly close below ~$22 (20-week EMA) on volume; a fresh dilutive raise before the catalyst; or the luvelta out-licensing process collapsing (signals the pivot asset has no taker).
  • Saturation tell: CNBC/retail-front-page coverage of STRO + the run already at/through $48 PTs before data — that's mean-reversion territory, not entry.

Correlation Notes

  • Trades with the ADC / precision-oncology cohort (IMNM/RVTSO-type single-name ADCs, broader XBI/IBB biotech beta). Risk-on biotech tape + falling rates lift the whole group; an XBI rollover drags STRO regardless of company news.
  • High idiosyncratic / binary weighting: on the STRO-004 readout day the name decouples from sector and trades on its own data. Position so a single-name gap doesn't blow the book — keep it a probe-sized bet given the binary.
  • Beta 1.55 — amplifies both market direction and any ADC-sector sentiment swing (e.g., a peer's failed TF-ADC or ADC-tox headline bleeds in).

Sources